Hereditary Diffuse Gastric Cancer
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
CDH1,
IL1RN,
KRAS,
TP53,
CTNNA1,
MUTYH,
APC,
MAP3K6,
MYC,
EGFR,
CHEK2,
TFAP2C,
TWIST1,
UMPS,
TYMS,
STAT3,
TBX3,
TGFA,
TPM3,
XRCC3,
TNF,
TIMP3,
THBD,
XRCC1,
ACTC1,
ZNF177,
PLPP1,
SELENBP1,
FCGBP,
SUCLG1
CDH1,
IL1RN,
KRAS,
TP53,
CTNNA1,
MUTYH,
APC,
MAP3K6,
MYC,
EGFR,
CHEK2,
TFAP2C,
TWIST1,
UMPS,
TYMS,
STAT3,
TBX3,
TGFA,
TPM3,
XRCC3,
TNF,
TIMP3,
THBD,
XRCC1,
ACTC1,
ZNF177,
PLPP1,
SELENBP1,
FCGBP,
SUCLG1,
TNFSF9,
IRS2,
AKR1C3,
CST7,
SREBF2,
ITGA8,
BAP1,
ARID1A,
MIA,
SYMPK,
TAF15,
PSCA,
SOD2,
SPRR2A,
RARB,
PTPRG,
PTPRF,
PTGS2,
KLK10,
PRNP,
MAPK8,
MAPK3,
MAPK1,
PRKCB,
PRKAB1,
PRKAA1,
PREP,
PTPA,
PPP2R1A,
PPIC,
RAD23A,
RARRES1,
RRP9,
RBP1,
SNRPB,
SNAI1,
SLC1A2,
RXRB,
RPS26,
RPS21,
RPS19,
RPS15,
RPS6,
RPL18,
RPL15,
RPL13,
RORA,
RGS2,
RBP4,
SLC16A3,
WDR46,
AURKB,
PUS1,
FAT4,
FSD1,
MRPS11,
HRH4,
KMT2C,
RANBP10,
EXOSC5,
GKN1,
CHFR,
NAXD,
RNF43,
XAF1,
KRT20,
PTOV1,
WWOX,
EPHX3,
ULBP2,
NBAS,
URM1,
ZNF667-AS1,
HOTAIR,
PRR5-ARHGAP8,
ATP6V0D2,
DCBLD2,
MBD3L2,
LRRC3B,
ZNF160,
MIR22HG,
TUBA1C,
SPZ1,
KISS1R,
ZNF559,
ARFGAP2,
REG4,
POLR3K,
HIKESHI,
IL32,
PRDX5,
FAM168A,
WIF1,
CCT7,
ARL6IP5,
NOP56,
FST,
DLC1,
CNPY2,
MSLN,
EBI3,
TRAP1,
SCRN1,
MTSS1,
TMEM63A,
PLIN2,
BOP1,
SERBP1,
GMPR2,
ZBTB20,
PLCE1,
ZNF593,
UBXN1,
COPS7A,
ZNRD1,
CPSF1,
ABT1,
PYCARD,
MRPL13,
MRPS18B,
PRPF19,
FILIP1,
SNX5,
ACAD8,
GREM1,
PPIA,
PPARG,
PLAU,
FGG,
DDB1,
ACE,
CYP2A6,
CTSL,
CTNNA2,
CST1,
CLDN3,
KLF6,
CLN3,
CLCN3,
CKB,
CTSC,
CDKN2D,
CDKN2A,
CDKN1B,
GADD45A,
DES,
DNMT1,
EEF1A2,
FBP1,
F2R,
ERCC2,
PLAGL1,
ERBB2,
ENO1,
EEF1A1,
DNMT3B,
ECM1,
ECHS1,
TYMP,
HBEGF,
DPYD,
DPAGT1,
CDKN1A,
CDK4,
CDH2,
ALDOB,
APOA1,
BIRC5,
BIRC2,
APEX1,
ANXA5,
ALOX5,
ALDH1A3,
RHOA,
ALB,
AHR,
AGTR2,
AFP,
ADRB2,
ADRB1,
AREG,
ATM,
CD44,
BNIP3,
RUNX3,
CAV1,
CASP10,
CASP8,
CA2,
CA1,
BMP7,
ALDH7A1,
BMP2,
BLVRB,
BID,
BDNF,
BCL2L1,
CCND1,
FGFR2,
ERCC1,
FHIT,
KISS1,
MUC1,
MTHFR,
MT2A,
MSX1,
MMP10,
MMP7,
KMT2A,
MLF1,
MET,
MARK1,
SMAD4,
M6PR,
FADS1,
FKBP2,
LGALS3,
MUC6,
MX1,
NDUFA2,
SERPINB2,
PIK3CA,
SERPINA1,
PHB,
PGAM1,
PDHA1,
PAX6,
SERPINE1,
NDUFS1,
PA2G4,
NT5E,
NPM1,
NOTCH2,
NOS3,
NDUFV1,
KRT8,
CCAT1,
HOXA2,
HNRNPL,
ICAM2,
HSPD1,
ID4,
IDH3B,
IGFBP3,
HSPB1,
HSPA8,
IGFBP7,
IL1B,
IL6,
HRAS,
IL6R,
HTR1A,
CXCL8,
HMOX1,
GSTP1,
TNFRSF9,
ING1,
IRF1,
GLI3,
ITGA5,
FYN,
JUN,
GAST,
REG1A,
MLH1,
MRC1,
DSG2,
FZR1,
PALB2,
CTNNB1,
DSG1,
DNAJB4,
ST8,
MRE11,
BRCA1,
BRCA2,
CTNND1,
MIR21,
TGFBR2,
TFF2,
JUP,
CDX2
Drugs
Bevacizumab
(
Equidacent,
AVASTIN,
Aybintio,
MVASI
),
Catumaxomab,
Chimeric monoclonal antibody against claudin-18 splice variant 2
Bevacizumab
(
Equidacent,
AVASTIN,
Aybintio,
MVASI
),
Catumaxomab,
Chimeric monoclonal antibody against claudin-18 splice variant 2,
Everolimus
(
AFINITOR,
VOTUBIA
),
G17(9) gastrin-diphtheria toxoid conjugate,
Human anti-guanylyl cyclase C monoclonal antibody linked to monomethyl auristatin E,
Ipatasertib,
Plevitrexed,
Ramucirumab
(
GILOTRIF,
CYRAMZA
),
Rilotumumab,
Tegafur, Gimeracil, Oteracil
(
TEYSUNO
),
Tesetaxel
Registered!
Hereditary diffuse gastric cancer is a rare epithelial tumor of the stomach, characterized by the development of diffuse (signet ring cell) gastric cancer at a young age, associated with germline heterozygous mutations of CDH1, MAP3K6 and CTNNA1 genes. In early stages it presents with non-specific and vague symptoms, in advanced stages it may cause nausea and vomiting, dysphagia, loss of appetite, abdominal mass or weight loss. Women have an increased risk of lobular breast cancer as well.